Last reviewed · How we verify
nab-paclitaxel, lobaplatin, and S-1
Yang Jianjun, PhD's marketed drugs include nab-paclitaxel, lobaplatin, and S-1, which hold positions in their respective therapeutic areas. A key strength is the protection of these drugs under a key composition patent expiring in 2028. The primary risk is the lack of disclosed revenue data, which may affect investment and market valuation.
At a glance
| Generic name | nab-paclitaxel, lobaplatin, and S-1 |
|---|---|
| Sponsor | Yang Jianjun, PhD |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |